Background Understanding the real-world effect of pneumococcal conjugate vaccines (PCVs) on pneumonia mortality is crucial because of the expectation that increased PCV use will substantially reduce the burden of pneumonia deaths in children younger than 5 years. However, few post-vaccine introduction studies have estimated the benefits of PCV use on childhood mortality and results have been inconsistent. Therefore, we set out to assess the effect of introduction of ten-valent pneumococcal conjugate vaccine (PCV10) on pneumonia mortality in children in Brazil.
Introduction
Pneumonia, despite substantial progress in prevention and treatment, is still the leading cause of death due to infectious diseases in children younger than 5 years, causing between 812 000 and 1·1 million deaths in children annually. 1 More than half of all global pneumonia deaths in children are thought to be caused by Streptococcus pneumoniae (the pneumococcus), 2 a bacterial pathogen that also causes invasive pneumococcal disease.
Pneumococcal conjugate vaccines (PCVs) have been introduced globally to reduce the burden of morbidity and mortality due to pneumococcus. The first formu lation, a sevenvalent PCV (PCV7), was introduced in 2000. Higher valency versions are now in use, covering ten (PCV10) and 13 (PCV13) serotypes. Administered to infants in a multidose schedule, PCVs are included in the national immunisation programmes of 135 countries. 3 PCVs are expensive and could increase total costs of the WHO Expanded Programme of Immunisation by 60-80%. 4 Thoroughly understanding the realworld benefits of PCVs is, therefore, doubly important.
Postintroduction studies of effectiveness have shown that PCVs reduce hospitalisations for invasive pneumo coccal disease and pneumonia and provide indirect (herd) protection to unvaccinated older children and adults in highly vaccinated populations. 5, 6 The vaccine reduces carriage of covered serotypes throughout the population and, in some countries, vaccine serotypes have been almost eliminated. 7 Invasive pneumococcal disease caused by pneumococcal serotypes not covered by the vaccine generally increases after vaccine intro duction. Despite this replacement, a literature review 7 found a net benefit against invasive pneumococcal disease in children, whereas, in some adult age categories, increases in nonvaccine serotypes completely offset invasive pneumococcal disease declines in vaccine targeted serotypes. However, preventing pneumonia deaths among children is the fundamental goal of the global effort to introduce PCVs. For example, WHO estimates that PCV use could reduce global childhood pneumonia mortality by up to 30% 8 and urges PCVs to be a priority in all countries, especially in those with the highest mortality in children younger than 5 years. 9 Although it stands to reason that fewer children will die from pneumonia if fewer children fall ill with pneumonia, surprisingly few published studies have estimated the benefit of PCVs for childhood pneumonia mortality after PCVs have been introduced. Therefore, we set out to assess the effect of PCV10 introduction on pneumonia mortality in children in Brazil. Brazil is a promising setting for such an assess ment because PCV10 coverage rose rapidly after its 2010 introduction, meaning benefits should become apparent quickly; long time series of detailed recordlevel vital statistics data are available; and Brazil has substantial geographical disparity in wealth, allowing the comparison of effective ness among children from different socioeconomic groups. Our analysis should shed light on PCV benefits in poor countries where the pneumonia burden is large, but vital statistics data are largely unavailable.
Methods

Study design and data sources
We accessed publicly available mortality data of children aged 59 months or younger between 1980 and 2014, coded according to the International Classification of Diseases tenth edition (ICD10), from the Mortality Information System of the Brazilian Ministry of Health. 10 We separated data into three age groups for analysis: children aged 3-11 months, 3-23 months, and 3-59 months. Infants aged 0-2 months were excluded to avoid perinatal causes of mortality-a major source of childhood mortality in Brazil 11 not preventable by PCV. Data on births and deaths are systematically collected throughout the year in Brazil, and covered approximately 95% of the popu lation in 2010. 12 We assessed allcause pneumonia for all analyses, defined as ICD10 codes J12-18, as the primary cause of death; these represented 65% of all respiratory deaths (ICD10 J00-99) among children in 2010. 10 For the ICD-10 see https://icd. who.int/browse10/2016/en
Research in context
Evidence before this study Since 2000, pneumococcal conjugate vaccines (PCVs) have been introduced in more than 100 countries to reduce the burden of pneumococcal disease. Post-marketing effectiveness studies have shown that PCVs reduce hospitalisations for invasive pneumococcal disease and pneumonia. However, organisations charged with implementing PCV programmes expect most to achieve a reduction in childhood pneumonia mortality. For example, WHO has stated that PCVs could reduce global pneumonia mortality in children by up to 30% and thus, should be a priority in all countries, especially those with the highest pneumonia burden. Despite such hopes, the peer-reviewed literature on PCV-related mortality reduction is scarce. We searched PubMed, Google Scholar, and Scielo for peer-reviewed post-marketing studies on the effect of PCVs on pneumonia mortality using the terms "pneumonia", "pneumococcal vaccine/s", "conjugate vaccine/s", "PCV", "pneumococcal", "impact", and "effectiveness". We included studies analysing changes in pneumonia mortality data before and after PCV introduction for any paediatric age group up to Dec 31, 2017, published in English, Spanish, and Portuguese, and excluded studies limited to in-hospital mortality. We identified only five post-marketing effectiveness studies; of these, three were set in a subnational population. Results were inconsistent, with benefits ranging from negligible to very large. Therefore, we set out to assess the effect of ten-valent pneumococcal conjugate vaccine (PCV10) on childhood pneumonia mortality in Brazil, a large country with high national vaccine coverage and substantial disparity in wealth, allowing comparisons of effectiveness among children from different socioeconomic groups.
Added value of this study
Brazil added PCV10 to its national vaccine schedule in 2010. We found that between 1980 and 2010, childhood pneumonia mortality decreased by 10 times in Brazil, concomitant with socioeconomic developments that led to improved education, sanitation, and public health. Regarding the effect of PCV10, we found weak evidence that introducing the vaccine produced a further reduction in childhood pneumonia deaths of about 10% at the national level. After stratifying by socioeconomic status, we found larger reductions in the subpopulation living in municipalities characterised by poverty or low maternal education, but no decline in the more affluent municipalities.
Implications of all the available evidence
Although a vaccine-related decrease in childhood pneumonia mortality of 10% is less than what many expected, our estimates indicate that the vaccine had a substantially greater benefit in poor municipalities in Brazil. These results imply that although the effect of PCV on paediatric pneumonia mortality might be reduced in countries where mortality rates have already fallen because of economic and social improvements, substantial vaccine-related gains are more likely in the world's low-income regions. Because reliable vital statistics data are largely unavailable in these countries, where pneumonia mortality is still high, assessing these gains will be difficult.
We stratified Brazil's 5570 municipalities into low, medium, and high socioeconomic status (SES) categories in three distinct ways, on the basis of data from 2010. We first stratified municipalities by their Human Develop ment Index (HDI) 13 -a composite measure of income, education, and longevity-into the categories very low or low (<0·60), medium (0·60 to <0·70), and high or very high development (≥0·70). The geographical distribution is shown in figure 1 . Because vulnerability to pneumonia and access to treatment can vary with other SES factors not easily captured by a general index such as HDI, we also stratified municipalities by the proportion of children living in extreme poverty (monthly per capita income <US$40) 14 and the proportion of mothers with no primary education; 15 both of which have been recognised as important risk factors for severe pneumonia in children. 16 For percentage of children in poverty, we defined low SES as more than 27% of children from a municipality living in extreme poverty, and high SES as fewer than 3% of children living in extreme poverty (upper and lower quartiles of extreme poverty dis tribution). For maternal education, we defined low SES as more than 30% of mothers with no primary education in a municipality, and high SES as fewer than 10% of mothers without primary education (upper and lower quartiles of the distribution).
Population estimates for each municipality and age group were obtained from the Brazilian Institute of Geography and Statistics (censuses 1991, 2000, and 2010 ). Monthly population data for SES strata were calculated by cubic polynomial interpolation of the agestratified and municipalitystratified census data with Popweaver, 17 a freely available interpolation software package.
We obtained PCV10 coverage data from the National Immunisation Programme. 18 The denominator for vaccine uptake was the number of children in each respective age band, estimated from monthly municipalityspecific livebirth data. 19 We used a cohort model that computes coverage in ageing cohorts of vaccinated infants from the numbers of doses administered in the postvaccination period 20 to estimate the proportion of children aged 6-23 months who received 3 or more doses of PCV10 or received the ageappropriate vaccine over time (eg, one catchup dose after age 1 year if not eligible for full series).
Procedures
The prevaccine period was from Additionally, because sparse data tend to be noisier, mortality analyses were based on quarterly instead of monthly time series (Q1: January-March, Q2: April-June, Q3: July-September, Q4: October-December). For each age group and demographic stratum, we compiled time series of pneumonia deaths per quarter. We used two complementary regression methods (synthetic control analysis and timetrend adjustment) to assess changes in pneumonia deaths after the introduction of PCV10. In both methods, the models were fit to data from the prevaccine period alone and controlled for seasonal variations with quarterly dummy variables. The regression models were then used to project how many cases of pneumonia would have occurred in the absence of PCV10 during the postvaccine period. Rate ratios were calculated by comparing observed and counterfactual rates in the postPCV10 period. In both methods, the data were fit in a Bayesian setting that allowed us to quantify uncertainty associated with variable selection and variation in the data. The approaches differed in how they adjust for changes unrelated to vaccine introduction.
We assessed the effect of PCV10 introduction on child hood pneumonia mortality, both at the national level and in high, middle, and low SES groups of municipalities.
Statistical analysis
We have previously described the synthetic control analysis method in the context of assessing the effect of PCV10 on pneumonia hospitalisations. 21 With this method, categories of mortality that were not expected to be influenced by the introduction of PCV10 were used as control variables in a regression. A time series for each control variable was constructed, and the scaled, logtransformed version of the time series was used as a covariate. Rather than using forwards or backwards variable selection, synthetic control analysis used a Bayesian variable selection method to determine the contribution of each possible control. Control time series that resembled the pneumonia time series more closely had higher weights, and irrelevant time series received weights closer to zero. These weights and regression coefficients were then combined with the observed values for the control time series in the postvaccine period to generate a counterfactual estimate.
In this study, we applied the synthetic control method 21 with a few adaptations. To construct the synthetic control, we used time series defined by ICD10 subchapters, in which disease codes are grouped in epidemiologically mean ingful categories. We excluded subchapters con taining codes that might be affected by PCVs from the synthetic control: all respiratory (J) subchapters; other bacterial diseases (A30-49); diseases of the middle ear and mastoid process (H65-75); bacterial, viral, and other infectious agents (B95-98); and inflammatory diseases of the central nervous system (G00-09).
In addition to the synthetic control analysis, we did a timetrend adjustment. We fit a simpler regression model in which the only control variables were a linear trend for time and quarterly dummy variables to adjust for seasonality; the offset term was all deaths that PCV10 could not be expected to prevent (nonPCV10preventable deaths). Because we included an offset for all non pneumococcal deaths, the interpretation of this model is effectively the extent to which pneumonia deaths changed relative to all other nonpneumococcalrelated causes. With this commonly used timetrend model, the counterfactual in the postvaccine period was generated by assuming that the prevaccine trends and seasonality continued into the postvaccine period. NonPCV preventable deaths were defined as all deaths except those coded as respiratory (any ICD10 J code), otitis media (H65-66), sepsis (A40-41), meningitis (G00-03 and A39), unspecified bacterial infection (A49), and encephalitis (G04). We did two validation analyses. In the first analysis, because completeness of vital registration data increased over time, we investigated whether adjusting for under reporting 22 would change our estimates. On the basis of data from the Brazilian Ministry of Health (2015), in which ill defined causes of death were proportionally redistributed on the basis of age, sex, Brazilian state of residence, and the relative proportion of deaths in each ICD10 chapter, we estimated correction factors for each age group, ICD10 chapter, year, and state as the ratio of adjusted to unadjusted mortality. We then used this ratio to adjust the time series of the outcome of interest (J12-18) and the ICD10 subchapters used to create the synthetic control. For the second validation analysis, we applied the synthetic control method to data from the period before PCV10 was introduced, We used the R statistical analysis software package for all analyses. The R code and mortality time series data can be downloaded from GitHub.
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Results
Pneumonia mortality in Brazilian children decreased by about 90% during 1980-2010, dropping from 147·0 to 16·1 annual deaths per 100 000 children younger than 5 years (figure 2). During these prePCV decades, Brazil transitioned from a lowermiddleincome to a high middleincome economy, and its HDI increased from 0·55 to 0·71. Reductions in annual rates of pneumonia mortality were steepest in the 1980s and 1990s. Therefore, most of the decline since 1980 was achieved before the millennium and preceded the introductions of the Haemophilus influenzae type B vaccine in 2000, and PCV10 in 2010.
We assessed raw trends in the years immediately before (2004-09) and after the 2010 introduction of PCV10 using both national data and data from Brazil's 5750 municipalities stratified by SES. During this period, national monthly pneumonia mortality rates declined modestly, but were essentially flat and continued to be flat thereafter (figure 2). A similar pattern was observed for nonPCVpreventable deaths (all deaths except those potentially affected by PCV10 introduction; appendix). We found that the low SES strata-on the basis of HDI, proportion of children living under extreme poverty, See Online for appendix and proportion of mothers without primary school education-had higher rates of pneumonia mortality at the time of PCV10 introduction in 2010 than those of the high SES strata (table 1) . Time series of pneumonia mortality rates in municipalities stratified by any of the three levels of HDI did not visibly change after 2010 (figure 3; appendix). PCV10 uptake was lower in the lower SES groups than in the higher SES groups during the first 2 postPCV years, but these differences faded by mid2012, as PCV10 coverage reached high levels (80-85% of the target population) in all strata (appendix).
We assessed declines in childhood pneumonia mortality associated with PCV10 use, adjusting for nonvaccine related trends with the synthetic control method. At the national level, the point estimates of the rate ratios were about 0·9 in the three age groups, corresponding to a reduction of about 10% (figure 4, appendix). These estimates had substantial uncertainty, and all credible intervals (CrIs) included 1 (signifying no effect): the estimated reduction was 12% (95% CrI -6 to 12) for children aged 3-11 months, 12% (-6 to 13) for children aged 3-23 months, and 8% (-9 to 19) for children aged 3-59 months. However, we detected a pattern of larger decreases in postPCV10 pneumonia mortality-decreases with 1 outside the CrI-in all three paediatric age groups in municipalities with a high percentage of extreme childhood poverty and mothers with no primary education (figure 4). For example, in the 3-23 months group, the mortality reduction was 19% (95% CrI 7-28) in high poverty municipalities and 24% (7-35) in municipalities with low maternal education ( figure 4; appendix) . This pattern of decreases was not present when we stratified by HDI, where the middle stratum had the largest estimated decrease. A consistent trend towards larger mortality decreases among successively less privileged populations in all three age groups was clear when SES was stratified by maternal primary education.
In addition to the primary synthetic control analysis, we did a simpler timetrends adjustment. We observed a pattern of results similar to the primary analysis, but with narrower CrIs. As a result, the estimated declines in pneumonia mortality in all three lowSES status strata and in all age groups had the upper bound of the CrIs below 1 (figure 4; appendix).
As a validation of the primary analysis, we applied the synthetic control model to a time period when no vaccine effect would be expected; we used April, 2004-March, 2007, as the training period and April, 2007-March, 2009 , as the evaluation period. Most point estimates were lower than 1, and the three lowSES strata had CrIs that were below 1. This potentially indicates uncontrolled con founding in these strata. However, CrIs for the rate ratios of most strata included 1 (appendix).
We investigated the effect of adjusting the data for underreporting of deaths and found that doing so made no difference in the point estimates or CrIs produced in either synthetic control or timetrend analyses and did not affect any of the observed trends or conclusions.
Discussion
In this study, we observed a large decrease in childhood pneumonia mortality in Brazil between 1980 and 2010, concomitant with the rapid socioeconomic development of the country and probably driven by many factors, including improved nutrition, housing, education, and access to health care, especially antibiotic drugs. We assessed the effect of the introduction of PCV10 in 2010, at national and municipality levels and controlling for continuing trends associated with development. With two different statistical models, we found modest evidence for a reduction in national pneumonia mortality in the two age groups with children younger than 24 months. Because this was a populationlevel estimate, it captured the effects of both serotype replacement, which would tend to reduce the benefit observed, and herd immunity, which would tend to increase it.
How do these national estimates compare with expectations? WHO has stated that childhood pneumonia mortality could be reduced by 30% if PCVs were used everywhere. 8 A frequently cited randomised controlled trial 23 of ninevalent PCV done in The Gambia in the early 2000s found, in a posthoc analysis, that the vaccine reduced allcause childhood mortality by 16%-a far broader endpoint and, thus, a much larger benefit than the reduction that WHO states could be achieved in pneumonia mortality alone. Estimates from the handful of published postintroduction studies of the effect of PCV use on childhood pneumonia mortality are variable, although the benefits are generally larger than those we found in Brazil; one study from Brazil 24 reported no benefit, whereas another from Chile 25 estimated an extraordinarily large benefit (table 2) .
Although we only detected a modest reduction in childhood pneumonia mortality at the national level after PCV10 introduction, we reported more substantial declines in less privileged populations, with point estimates of the vaccineassociated decline of 16-24% among the smaller subset of children from areas with a high proportion of mothers with low education. Several factors could explain the discrepant patterns between children from higher SES and lower SES. For example, higher SES might be associated with changes in the proportion of pneumonia caused by pneumococcus or with better diagnosis and access to treatment. Our results suggest that in lowincome countries, where the paediatric pneumonia mortality burden is larger and timely access to care and maternal knowledge about disease are scarcer than in developed countries, the mortality reduction after introduction of PCVs might be larger than in higherincome nations.
Our study has limitations. Although the synthetic control method we used to detect the benefits of PCV introduction was explicitly designed to minimise confounding, the method is, at heart, an ecological study design and other uncontrolled factors might have affected the estimates. For example, it is possible that our estimates were confounded by antibiotics becoming prescriptiononly drugs in Brazil in the same year that PCV10 was introduced. 31 Moreover, we relied on ICD10 codes being mostly accurately assigned, and we assumed that no substantial changes in the probability of miscoding happened over time. However, our study assessed all paediatric deaths in the entire country over multiple years; to the extent that PCV10 indeed had a substantial effect on childhood pneumonia mortality, we were probably able to estimate it accurately.
The massive reduction in childhood pneumonia mortality observed in Brazil after 1980, and before the introduction of PCV10, underscores the often under appreciated power of improved nutrition, health care, education, and living conditions to save lives. Although we cannot know what the effect of PCV10 might have been in Brazil had it been introduced in 1980, our SESstratified results suggest that the effect would have been considerably greater than it was in 2010. To the extent that Brazil's poorer regions can act as a proxy for lowincome countries elsewhere, our study suggests that the power of PCVs to save children's lives is likely to be greatest in countries that are less economically developed, and where the burden of pneumonia mortality is still high.
Contributors LS, CSP, RJT, and DMW conceived the study. CSP and WJA did the analyses. CSP, LS, and RJT did the literature search. LS, CSP, and RJT wrote the first draft. All authors contributed to and read the final draft of the manuscript.
Declaration of interests
DMW previously received an investigatorinitiated research grant from Pfizer and consulting fees from Pfizer, Merck, GlaxoSmithKline, and Affinivax. LS and RJT own Sage Analytica, a research consultancy with government and nongovernment clients, which received an investigatorinitiated research grant from Pfizer (completed in 2013). The number following PCV indicates the number of serotypes covered by the vaccine. Pre-post=a study that compared rates in the pre-vaccine period to rates in the post-vaccine period. NA=not applicable.
LRI=lower respiratory tract infection. *Codes of the International Classification of Diseases tenth edition. †Some authors based the estimate on last year in study, others on more than 1 post-PCV years. 
